DANA-FARBER CANCER INST
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer is a funding opportunity from DANA-FARBER CANCER INST, up to 407175, closing March 31, 2027.
Mar 31, 2027
(243d left)Overview
PROJECT SUMMARY Despite the therapeutic promise of STING agonists in cancer, first in human studies have been hampered by lack of precision therapy and issues with drug delivery. My laboratory studies triple negative breast cancer (TNBC), a highly aggressive breast malignancy with limited therapeutic options and a…